Total joint arthroplasty, obesity itself is not a reason to delay the new operation

Published Date: 17 Mar 2023

The American College of Rheumatology (ACR) and the American College of Hip Surgery (AAHKS) have released new guidelines.

Read Full News

Latest News

Enzyme provides promising path to degenerative joint diseases cure

Degenerative joint diseases like osteoarthritis and intervertebral disk degeneration are conditions that affect millions of people worldwide, leading to pain and reduced mobility. These diseases remain incurable because current ...

New points to consider in treatment-resistant psoriatic arthritis

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to treatment. EULAR—The European Alliance of Associations for Rheumatology—has released new evidence-based ...

Study finds improvement in knee pain with exercise and physical therapy

People with a meniscal tear and osteoarthritis prescribed home exercises with or without physical therapy reported substantial improvements in knee pain, according to a new study led by Mass General Brigham researchers.

New genetic marker could improve prediction of severe gout drug reactions in US patients

A newly identified genetic marker may significantly improve the ability to predict life-threatening reactions to the gout medication allopurinol in U.S. patients.

SGLT-2 inhibitors tied to lower risk for autoimmune rheumatic diseases in adults with type 2 diabetes

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes, according to a study published online ...

Simple screening tool can help uncover underdiagnosed back condition, study finds

For millions of people living with back pain, the cause is often elusive. One underrecognized culprit is axial spondyloarthritis (axSpA)—a form of inflammatory arthritis that primarily affects the spine and sacroiliac joints ...

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Latest News

Degenerative joint diseases like osteoarthritis and intervertebral disk degeneration are conditions that affect millions of people worldwide, leading to pain and reduced mobility. These diseases remain incurable because current ...

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to treatment. EULAR—The European Alliance of Associations for Rheumatology—has released new evidence-based ...

People with a meniscal tear and osteoarthritis prescribed home exercises with or without physical therapy reported substantial improvements in knee pain, according to a new study led by Mass General Brigham researchers.

A newly identified genetic marker may significantly improve the ability to predict life-threatening reactions to the gout medication allopurinol in U.S. patients.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes, according to a study published online ...

For millions of people living with back pain, the cause is often elusive. One underrecognized culprit is axial spondyloarthritis (axSpA)—a form of inflammatory arthritis that primarily affects the spine and sacroiliac joints ...

News All Time

Seven-year study reveals rheumatoid arthritis begins long before symptoms, opening door to prevention 

Scientists have discovered that rheumatoid arthritis (RA) doesn't start when the pain begins. It silently starts years earlier. RA is a debilitating autoimmune disease that causes painful joint inflammation and damage. The ...

Self-guided online program improves quality of life in rheumatoid arthritis, psoriatic arthritis and lupus

Patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus frequently face anxiety and depression along with chronic physical symptoms. Reported rates of depression range from 15% to 24% and ...

Analysis isolates population aging as primary driver of musculoskeletal disorders

Novel research shows that in approximately one third of countries and territories worldwide, population aging was the largest contributor to the growing burden of musculoskeletal disorders from 1990 to 2021.

Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual ...

Current research may open doors to new treatments for children with juvenile dermatomyositis

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).

Squishy 'smart cartilage' could target arthritis pain as soon as flareups begin

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.

Immune aging may be a driver of rheumatoid arthritis rather than a consequence

Features of immune system aging can be detected in the earliest stages of rheumatoid arthritis (RA), even before clinical diagnosis, a new study has found which provides at-risk individuals with hope for early intervention.

Common arthritis drug found to lower blood pressure and risk of heart disease

Methotrexate, a common medication used to treat rheumatoid arthritis, has a newly recognized useful secondary effect of lowering blood pressure and potentially reduces the risk of heart disease in people with this condition.

Noisy knees not an early arthritis sign, says new study

Knee crepitus, the sound of cracking or grinding in the knee joint, is very common across all age groups.

Q&A: These genetic insights into rheumatoid arthritis could help design better treatments

People with rheumatoid arthritis (RA) often have trouble getting out of bed in the morning, let alone getting to the rheumatologist for a checkup or participating in a research study. This makes a deeper understanding of ...

Benefits of long-term routine lab drug toxicity monitoring unclear in rheumatoid arthritis

For patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs), long-term routine laboratory toxicity monitoring (lt-RLTM) indicates that most very abnormal laboratory results are already ...

Back pain a $638 billion productivity black hole, Australian study warns

A new study from Monash University has revealed that long-term back problems will cost the Australian economy an estimated $638 billion in lost productivity over the next decade unless urgent action is taken.

Survey reveals people are not aware knee and groin pain can be signs of hip problems

Having a hard time bending over to put your shoes on? Experiencing pain in the knees, groin, thigh or back? A survey by The Ohio State University Wexner Medical Center reveals many people don't realize these symptoms can ...

Improving prediction of worsening knee osteoarthritis with an AI-assisted model

An artificial intelligence (AI)-assisted model that combines a patient's MRI, biochemical, and clinical information shows preliminary promise in improving predictions of whether their knee osteoarthritis may soon worsen. ...

Scientist uncover hidden immune 'hubs' that drive joint damage in rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease that affects millions worldwide and can have a devastating impact on patients' lives. Yet, about one in three patients respond poorly to existing treatments.

Lupus low disease activity state attainable in lupus nephritis

In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated with best relapse-free survival, with independent associations seen with ...

Recommended News For You

Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia

The FDA Approves the New Frontline Aggressive ALL Regimen.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Hypnotherapy may offer real benefits for cancer patient care

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

Oncology Drug Shortages Persist, but Continue to Evolve

Recommended Articles For You

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

The Importance of Maintaining Normal Calcium Levels in Your Body  

Understanding Axitinib: What You Need To Know For Your Treatment Plan 

Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recently released national data on drug use and abuse among Americans.

2.

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

3.

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

4.

Scholastic performance is a key concern for young cancer patients, study finds

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

1.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

2.

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology

3.

Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances

4.

A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy

5.

Clinical Analysis of Prostate Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Navigating the Complexities of Ph Negative ALL - Part XI

5.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot